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ABSTRACT
Background: Chronic degenerative mitral valve disease (CDMVD) continues to be the most common cause of heart failure 
(HF) in small breed dogs. Pimobendan (PIMO) is a mixed action drug with inotropic and vasodilator properties and is 
widely used to treat heart disease in dogs. Therefore, PIMO increases cardiac output, reduces both preload and afterload 
and increases myocardial contractility without increasing energy consumption and myocardial oxygen. Digoxin (DIG) is 
a cardiac glycoside acting through inhibition of the sarcolemmal Na+/K+ ATPase pump, hence increasing intracellular 
calcium. It exerts benefi cial effects on left ventricular function, symptoms and exercise tolerance. The purpose of this 
prospective, randomized, double blind clinical trial was to evaluate the clinical response and QoLQ in heart failure (HF) 
dogs treated with digoxin or pimobendan in addition to conventional therapy (furosemide and benazepril).
Materials, Methods & Results: Inclusion criteria: dogs in class III or stabilized class IV (NYHA). Exclusion criteria: use of 
positive inotrope and antiarrhythmic, presence of atrial fi brillation, renal or hepatic disease or neoplasia. Thirty three dogs 
were included and randomly assigned to DIG (n = 11), PIMO (n = 14) and placebo (PL) (n = 8) and followed up weekly. 
Data was evaluated for days zero, 7, 14 and 28. Increasing score was assigned to each variable depending on worsening 
of clinical evaluation (history and physical exam, QoLQ and echocardiogram (echo).Three dogs died during treatment 
due to worsening of HF, one of PL group and two of DIG group; furthermore, one of PIMO group was censored due to 
worsening of heart failure. There was no signifi cant difference between and within groups for echo and radiography. PL 
and DIG groups did not show any signifi cant difference throughout the 28 days of treatment. PIMO group showed lower 
physical exam score and increased early mitral infl ow velocity on day 28. Serum creatinine increased on days 14 and 28 
compared to baseline, but within normal limits. The groups were similar within each evaluation day.
Discussion: This is the fi rst short term prospective randomized double blind study comparing PIMO to DIG or PL ad-
ditionally to conventional therapy (ACEi and furosemide) for dogs with HF due to CDMVD. It was observed an early 
signifi cant clinical improvement in dogs receiving PIMO compared to those receiving DIG or PL. The increase in early 
mitral infl ow velocity (E-wave) on day 28 for PIMO group is suggestive of diastolic dysfunction improvement, but this is 
only one variable related to diastolic function. Creatinine concentration increased in PIMO group, although it remained 
within normal range. In the present study, although all the three groups received furosemide, only PIMO group showed 
increase in blood creatinine between baseline and days 7 and 28. This result must be explored in later studies. Regarding the 
exercise intolerance assessment in a QoLQ, it must be aware that the owner evaluation is strongly infl uenced by the level 
of exercise that the dog is regularly submitted. Considering that most of the times, small breed dogs in a more advanced 
age is probably more sedentary and this fact surely precludes the owner to assess the exercise capacity. A more objective 
evaluation of the exercise tolerance should be considered in further clinical trials. Probably because of the small number 
of animals included in this study, differences in other studied variables were not found. The short-term follow-up of these 
patients may also have infl uenced the lack of differences among groups. Considering that stronger clinical evidence is 
needed to guide clinical decisions, longer prospective studies are also needed to compare the effects of DIG and PIMO, as 
well as to consider the benefi ts of the use or not of DIG associated with PIMO for dogs in HF due to CDMVD.
Keywords: treatment, inotropic drug, angiotensin converting enzyme inhibitor, furosemide.
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INTRODUCTION
Pimobendan (PIMO) is a mixed action drug 
with inotropic and vasodilator properties and is widely 
used to treat heart disease in dogs [3,7]. It is a benzida-
zole-pyridazinone derived that exerts effect by combi-
ning inotropic and vasodilator calcium sensitization to 
troponin C and inhibition of phosphodiesterase [3,17]. 
Therefore, PIMO increases cardiac output, reduces 
both preload and afterload and increases myocardial 
contractility without increasing energy consumption 
and myocardial oxygen [11]. Its use has shown good 
results in dogs with myxomatous mitral valve [11,12] 
and in dogs with dilated cardiomyopathy [14]. Digoxin 
(DIG) is a cardiac glycoside acting through inhibition 
of the sarcolemmal Na+/K+ ATPase pump, hence 
increasing intracellular calcium. It exerts benefi cial 
effects on left ventricular function, symptoms and exer-
cise tolerance [13]. Some clinical studies have shown 
that PIMO leads to clinical improvement as well as of 
quality of life (QoLQ), but mostly, the comparison was 
made with placebo or benazepril, and not with another 
positive inotrope. Thus, the aim of this study was the 
clinical evaluation and quality of life questionnaire 
(QoLQ) as well as systolic arterial blood pressure 
(SAP), electrocardiography (ECG), echocardiography 
(ECHO), thoracic radiography, hematological and 
biochemical parameters in dogs with HF caused by 
CDMVD (associated or not with tricuspid insuffi ciency 
without right ventricular failure signs), submitted to 
conventional therapy (ACEi, furosemide), with and 
without DIG compared to conventional therapy asso-
ciated to PIMO.
MATERIALS AND METHODS
This study was performed between November 
2009 and November 2011 at the Veterinary Medical 
Teaching Hospital, School of Veterinary Medicine 
and Animal Science, University of São Paulo and at 
PROVET Laboratory of Hormone Testing. The owners 
of the dogs used in this study were informed about the 
research study proceedings, who signed a consent and 
commitment form. 
A prospective, randomized, double-blinded, 
placebo-controlled study was conducted. Small breed 
dogs (up to 15 kg), independent of gender, age and 
breed defi nition, with HF clinical signs were assessed 
by anamnesis, physical exam (PE), ECG1, thoracic 
radiography2, ECHO3, systolic arterial blood pressure 
(SAP)4 hematological and biochemical profi le, as well 
as electrolytes determination5 and thyroid function 
evaluation (free T4 and canine TSH)6.
Patients were classifi ed according to New York 
Heart Association (NYHA) [10], based on clinical 
exam. Only those in class III (having shown at least 
one episode of HF decompensation) were included 
in the study. Any patients showing signs of infection, 
endocrine diseases, hepatic changes or renal disease 
were excluded.
Information regarding anamnesis and physical 
exam were assigned a score to allow a more objective 
assessment. 
For anamnesis, the information considered was: 
cough (0=absent, 1=mild to moderate and 2=severe), 
lethargy/willingness to exercise (0=absent, 1=mild to 
moderate and 2=severe), exercise intolerance (0=absent, 
1=mild to moderate and 2=severe), and dyspnea (0=ab-
sent, 1=mild to moderate and 2=severe). The presence 
of seizure, syncope, presyncope, cyanosis, ascites and 
limbs edema were also considered (0=absent and 1=pre-
sent). Anamnesis score varied from zero to 14. 
Physical exam (PE) parameters were: general 
appearance (0=good, 1=regular and 2=compromised/
bad); respiratory pattern (0=eupneic, 1=tachypneic and 
2=dyspneic); hydration status (0=adequate/normal and 
1=dehydrated); mucous membranes (0=normal, 1=pale 
and  2=cyanotic), capillary refi ll time (CRT) (0=normal 
and 1=prolonged); femoral pulse (0=normokinetic, 
1=hyperkinetic and 2=hypokinetic); cardiac rhythm 
(0=regular and 1=irregular); cardiac sounds (0=nor-
mophonesis, 1=hyperphonesis and 2=hypophonesis); 
cardiac murmur grade varying from 1 to 6 based on 
Friedman’s scale) and, pulmonar auscultation (0=no 
alteration, 1=focal crackles and 2=generalized crack-
les). PE score varied from zero to 27.
A QoLQ questionnaire was also used [11]. 
QoLQ assessed: exercise tolerance (0=very good, 1= 
good, 2=moderate, 3=bad and 4=very bad); cough 
(0=absent, 1=occasional, 2=frequent and 3=persis-
tent); respiratory effort (0=normal, 1=mildly increased, 
2=hard to breath and 3=”shortness of breath”; appetite, 
(0=increased, 1=normal, 2=decreased and 3=anorexia); 
mental status (0=alert and responsive, 1=mildly decre-
ased, 2=depressed and 3=little responsive); attitude 
(0=increased, 1=unaltered  and 2=decreased; physical 
activity (0=good, 1=moderate, 2=decreased, 3=minimal 
and 4=incapacitated. QoLQ score varied from zero to 22.
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ECG was evaluated based on Tilley [21]. Tho-
racic radiography was evaluated by Vertebral Heart 
Size (VHS) according to Buchanan and Bücheler [6], 
as well as for presence of congestion/edema. SAP was 
performed by non invasive technique, by Doppler me-
thod, as proposed by Brown et al. [5] and Ware [22].
Echocardiographic examinations were perfor-
med according to the American Society of Echocar-
diography (ASE) recommendations [2]. The M-mode 
parameters evaluated were as follows: thickness of the 
interventricular septum in diastole (IVSd); thickness 
of the left ventricular free wall in diastole (LVWd); 
ratio between IVSd and LVWd (septum/wall ratio); 
internal diameter of the left ventricular cavity in dias-
tole (LVDd); internal diameter of the cavity of the left 
ventricle in systole (LVDs); left ventricular ejection 
fraction (LVEF); fractional shortening (FS); heart rate 
(HR); aortic root (Ao); left atrium (LA); ratio between 
the aortic root and left atrium measurements (Ao/LA). 
Three measurements were performed for each echocar-
diographic parameter, and the mean of the three values 
was considered for analysis.
Hematological and biochemical profi le (liver 
enzymes, renal function and electrolytes), free T4 
(dialysis) and canine TSH were also performed.
This was a double-blinded study and only two 
collaborators were responsible for dispensing of drugs. 
Randomization was performed by drawing lots and just 
these collaborators knew which medication was used. 
Dogs were followed up for four weeks (28 days). 
Clinical evaluation (anamnesis, PE and QoLQ), ECG, 
ECHO, SAP, laboratory evaluation were performed on 
baseline (day zero), and then on days 7, 14 and 28 of thera-
py. Thoracic radiography was performed on baseline and 
day 28, and thyroid test (T4 and TSH) only on baseline.
The medications and doses used according to 
the group assignment were: ACEi (benazepril)7 0.5 
mg/kg SID, PO; furosemide8 2.0 mg/kg BID or TID, 
PO; DIG9 0.003 to 0.008 mg/kg BID, PO; PIMO10 0.2 
mg/kg BID, PO, 1 h before meal. PIMO was rema-
nipulated11 with Vetmedin®, sorbitol and potassium 
sorbate. PL containing sorbitol and potassium sorbate 
was manipulated11. All drugs evaluated (DIG, PIMO 
and PL) were compounded in liquid presentation from 
original commercial available formulations in order to 
ensure treatment blindness.
When death or need for further treatment inter-
vention that forced label opening occurred, scores were 
considered as maximum for the following evaluations, 
as an intention to treat design.
Shapiro-Wilk test was used to assess normality 
of distribution. Within group analysis was performed 
by Repeated measures ANOVA followed by Tukey-
-Kramer as post hoc test (for parametric data) and 
Friedman’s test followed by Dunn for nonparametric 
data. For comparison between groups, ANOVA was 
used followed by Tukey as post hoc test for parametric 
data and Kruskal-Wallis followed by Dunn for nonpa-
rametric data. Signifi cance was considered when P < 
0.05. Statistical analysis was performed using commer-
cial available software (GraphPad InStat 3 version 3.05, 
GraphPad Software, San Diego, California, USA).
RESULTS
Forty nine animals were screened, but 16 
were excluded with different diagnosis or incident 
comorbidities: pancreatitis (1), absence of edema and 
congestion (2), urolithiasis (1), abdominal neoplasia 
(2), death from heart failure before ECHO exam (3), 
liver disorders (1), breast cancer (1), epilepsy (1), 
atrioventricular block (1), dog owner was sick (1) and 
because ECHO machine broke during study (2). 
Thirty three dogs were included in the study, 
and were randomly allocated to three groups: group 
PL: 8 dogs treated with ACEi (benazepril), furose-
mide and PL; group DIG: 11 dogs treated with ACEi 
(benazepril), furosemide and DIG; group PIMO: 14 
dogs treated with ACEi (benazepril), furosemide and 
PIMO (Table 1).
For the comparison between groups, within each 
moment (Day 0 vs Day 7 vs Day 14 vs Day 28), the 
groups were similar for all the variables studied. At day 
28, there was a signifi cant difference among groups for 
physical exam score (P = 0.02), but it was not possible 
to identify the difference after the post hoc test.
For comparison among moments within each 
group, PL and DIG groups did not show any signifi cant 
difference throughout the 28 days of treatment. For 
PIMO group, anamnesis score decreased on day 14 
compared to baseline, but the difference did not reach 
signifi cance at day 28. PIMO group showed lower 
physical exam score on day 28 (P < 0.05). Quality 
of life questionnaire score was signifi cantly lower on 
day 7, but this difference did not reach signifi cance on 
days 14 and 28.
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There was an increase in early mitral infl ow 
velocity (E-wave) on day 28 for PIMO group. There 
was a signifi cant difference among groups for urea 
concentration, but the difference was not apparent after 
pos hoc test. Creatinine concentration increased on 
days 14 and 28 compared to baseline for PIMO group, 
although remaining within reference range for 13 out 
of 14 dogs, with slight increase in one dog (Table 2).
DISCUSSION
This is the fi rst short term prospective randomi-
zed double blind study comparing PIMO to DIG or PL 
additionally to conventional therapy (ACEi and furose-
mide) for dogs with HF due to CDMVD. We observed an 
early signifi cant clinical improvement in dogs receiving 
PIMO compared to those receiving DIG or PL. 
A Pubmed search using “Pimobendan” AND 
“Heart failure” AND “dogs” as search strategy recove-
red 28 articles, including six clinical trials. A modifi ed 
search with “Pimobendan” AND “dogs” recovered 80 
publications, 11 of which were clinical trials. Among 
these, one was focused on pulmonary hypertension and 
three were related to HF due to CDMVD comparing 
pimobendan (PIMO) and an angiotensin converting 
enzyme inhibitor (ACEi). These studies have shown 
that PIMO improves survival and heart insuffi ciency 
score. Although digoxin (DIG) is not a strong positive 
inotrope, it has been used for the management of heart 
failure in dogs with CDMVD when there is left ventri-
cular dilation or myocardial dysfunction. ACEis have 
been proved to have benefi cial effects on survival and 
quality of life in dogs with HF due to CDMVD, and 
therefore, are widely used with this purpose. Most of 
the studies, cited herein, evaluated PIMO compared to 
an ACEi; however, there is a lack of studies assessing 
the additional effects of PIMO on a standard therapy, 
which already includes ACEi and diuretics, nor has 
anyone compared PIMO to DIG besides a placebo (no 
positive inotrope). 
On a study comparing PIMO and ramipril in 
dogs with CDMVD, the authors reported that dogs in 
the ramipril group had a higher overall score on base-
line, and therefore, they may have had more advanced 
disease than the dogs treated with PIMO [19]. In the 
present study, all the groups were comparable (similar) 
on baseline. 
Table 1. Characteristics of groups regarding sample size, number of deaths and censored, age, weight, gender and breed of included patients.
Parameter
Groups Descriptions
PL group (n=8) DIG group (n=11) PIMO group (n=14) ALL groups (n=33)
Died 1 (12.5%) 2 (18.2%) 0 3 (9.1%)
Censored 0 0 1 (7.1%) 1 (3%)
Age (years) 12 (8-14) 10.8 (8-14) 11.9 (9-15) 11,6 (8-15)
Median (min-max)     
Weigh (kg) 6.6 (1.9-11.3) 6.8 (4.2-13.1) 6.1 (1.7-12.6) 6.5 (1.7-13.1)
Median (min-max)     
Gender 4 M(50%) 7 M (63.6%) 10 M (71.4%) 21 M (63.6%)
 4 F (50%) 4 F (36.4%) 4 F (28.6%) 12 F (36.4%)
Breed 2 Poodle (25%) 6 Poodle (54.5%) 8 Poodle (57.1%) 16 Poodle (48.5%)
 1 Pinscher (12.5%) 1 Teckel (9.1%) 2 Pinscher (14.3%) 3 Pinscher (9.1%)
 2 Teckel (25%) 1 Shih tzu (9.1%) 1 Yorkshire (7.1%) 3 Teckel (9.1%)
 3 MB (37.5%) 1 Schn. (9.1%) 3 MB (21.4%) 1 Shih tzu (3%)
  2 MB (18.2%)  1 Yorkshire (3%)
    1 Schnauzer (3%)
    8 MB (24.2%)
M: male; F: female; Schn: Schnauzer; MB: mixed breed.
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Table 2. Summary of statistics for anamnesis, physical exam, quality of life questionnaire scores, urea, creatinine and mitral infl ow velocities measured 
by Echo-Doppler. HOVET/FMVZ/USP. São Paulo, 2009-2011.
Within Groups Analysis
Variable Day PL group p value DIG group p value PIMO group p value
Post Hoc Test
PIMO Group
Anam. Score
0 3.63±2.72
0.11#
3.82±2.36
0.17#
2.86±2.25
0.002#* T0>T14£
7 1.63±1.85 1.73±1.49 0.93±1.07
14 1.63±1.41 3.36±5.39 0.86±1.10
28 2.63±4.75 3.18±5.40 1.57±3.67
PE Score
0 7.00±2.88
0.57#
7.82±3.63
0.88#
6.14±1.79
0.006#* T0>T28£
7 5.75±1.75 6.18±1.78 5.00±1.41
14 6.25±1.91 9.55±8.77 4.64±1.95
28 8.50±7.62 9.36±8.79 5.86±6.35
QoLQ Score
0 8.00±3.63
0.08#
6.18±2.48
0.10#
7.57±3.80
0.01#* T0>T7£
7 4.63±3.42 4.82±2.86 3.86±2.07
14 6.63±3.74 8.00±7.31 4.64±3.1
28 5.63±6.74 6.18±7.88 4.71±5.24
Ureia
0 78.06±22.32
0.69#
77.32±47.76&
0.25#
55.05±22.94&
0.04#* NS£
7 89.89±61.58 91.82±68.20& 70.92±20.23
14 87.96±46.03 94.59±59.42& 72.53±25.08
28 107.59±80.27& 92,91±49.03 74.03±33.44&
Creatinin
0 1.13±0.45&
0.24#
1.10±0.38
0.40#
0.85±0.30&
0.02§* T0<T14 and T28¢
7 1.22±0.64& 1.29±0.44 1.06±0.26
14 1.34±0.70& 1.31±0.39 1.03±0.31
28 1.35±0.76& 1.37±0.52& 1.06±0.36
E
0 1.29±0.32
0.84§
1.20±0.31
0.99§
1.38±0.24
0.03§* T0>T28¢
7 1,24±0.25 1.19±0.32 1.31±0.24
14 1.31±0.39& 1.12±0.32 1.28±0.25
28 1.36±0.33 1.13±0.30 1.23±0.17
A
0 0.69±0.12
0,484§
0.82±0.24
0,24§
0.70±0.17
0,567§ NS
7 0.76±0.19 0.84±0.24 0.68±0.18
14 0.80±0.25 0.70±0.17 0.70±0.14
28 0.77±0.17 0.75±0.15 0.66±0.14
E/A
0 1.92±0.65
0.62§
1.55±0.51&
0.18#
2.11±0.61
0.68§ NS
7 1.74±0.53 1.45±0.32 2.05±0.58
14 1.84±0.87 1.61±0.31 1.90±0.53
28 1.88±0.72 1.56±0.43 1.93±0.47
Anam.: anamnesis; PE: physical exam; QoLQ: quality of life questionnaire; Cr: creatinine; E: early mitral infl ow velocity; A: late mitral infl ow veloc-
ity; NS: no statistical difference; #Kruskal-Wallis rank sum test; §ANOVA for repeated measures; £Dunn’s Multiple Comparisons Test; ¢Tukey-Kramer 
Multiple Comparisons Test; &Shapiro-Wilk - Abnormal distribution; *Statistical difference.
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In a study published as an abstract that included 
15 dogs with CHF secondary to CDMVD receiving 
furosemide and benazepril or PIMO, the authors 
subjectively observed a 100% improvement on PIMO 
group and only 20% on the benazepril group [15].
Previous longer term studies also comparing 
PIMO and benazepril, observed a longer survival time 
for PIMO group with median survival of 415 compared 
to 128 days, respectively [12], and 267 days versus 140 
days, respectively [10]. The number of dogs included 
in the present study and the time of follow-up did not 
allow for survival analysis.
Dogs with asymptomatic DCMVD presented 
increase of left ventricular ejection fraction after 30 
days therapy with PIMO [16], differently from what 
was observed in our study in a 28 days follow-up.
The increase in early mitral infl ow velocity 
(E-wave) on day 28 for PIMO group is suggestive of 
diastolic dysfunction improvement, but this is only 
one variable related to diastolic function. Accelerated 
LV isovolumetric relaxation and improved distensibi-
lity was observed in an experimental study on pacing 
induced HF in dogs treated with PIMO [1].
Creatinine concentration increased in PIMO 
group, although it remained within normal range. This 
fi nding is surprising because, another experimental stu-
dy [11], with Beagles with induced CDMVD, observed 
increase of both renal blood fl ow and glomerular fi ltra-
tion rate in the second and fourth weeks using PIMO.
Alterations of renal function were not observed 
in healthy animals, receiving PIMO for seven days 
[9] and neither in a study of acute effects of PIMO 
and furosemide on renin-angiotensin-aldosterone 
system [18]. On the other hand, on a clinical study 
comparing effects of PIMO and benazepril, in Cavalier 
King Charles Spaniel dogs with CDMVD, despite the 
clinical improvement observed when low doses of 
furosemide were administered, there was an increase 
of blood creatinine levels [10]. In the present study, 
although all the three groups received furosemide, 
only PIMO group showed increase in blood creatinine 
between baseline and days 7 and 28. This result must 
be explored in later studies.
Regarding the exercise intolerance assessment 
in a QoLQ, we must be aware that the owner evaluation 
is strongly infl uenced by the level of exercise that the 
dog is regularly submitted. We must consider that most 
of the times, small breed dogs in a more advanced age 
is probably more sedentary and this fact surely preclu-
des the owner to assess the exercise capacity. A more 
objective evaluation of the exercise tolerance should 
be considered in further clinical trials.
Probably because of the small number of ani-
mals included in this study, differences in other studied 
variables were not found. The short-term follow-up 
of these patients may also have infl uenced the lack of 
differences among groups. In agreement with other 
study [17], further clinical trials are needed to better 
assess the effi cacy and safety of PIMO in dogs with 
CDMVD. Considering that stronger clinical evidence 
is needed to guide clinical decisions, longer prospective 
studies are also needed to compare the effects of DIG 
and PIMO, as well as to consider the benefi ts of the 
use or not of DIG associated with PIMO for dogs in 
HF due to CDMVD.
CONCLUSION
This short-term study suggests that dogs with 
CHF caused by CDMVD submitted to conventional 
therapy (ACEi and furosemide) associated with PIMO 
show early clinical improvement when compared to 
those receiving PLA or DIG.
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